Drug intelligence / Profile preview

Plasmodium falciparum Chimeric Protein 2.9 - Montanide ISA 720

Development stage
Unknown
Lead developer
Shanghai Wanxing Biopharmaceuticals
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

**Plasmodium falciparum Chimeric Protein 2.9 - Montanide ISA 720** is an investigational recombinant protein subunit malaria vaccine targeting the asexual blood stage of *Plasmodium falciparum*. Its active antigen, PfCP-2.9, is a single chimeric recombinant protein comprising domain III of *P. falciparum* apical membrane antigen 1 and the C-terminal 19 kDa fragment of merozoite surface protein 1, joined through a peptide hinge. It is formulated with the water-in-oil adjuvant Montanide ISA 720 to enhance antigen-specific immune responses. Vaccination is intended to induce antibodies recognizing native parasite AMA-1 and MSP1 epitopes and inhibiting blood-stage parasite growth and erythrocyte invasion. A Phase 1 study in healthy Chinese adults found the formulation generally safe, tolerable, and immunogenic, including high antigen-specific antibody titers in a subset of vaccine recipients. ([journals.plos.org](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0001952))

Other names
PfCP-2.9 formulated with Montanide ISA 720PfCP2.9 formulated with Montanide ISA 720PfCP 2.9 formulated with Montanide ISA 720PfCP-2.9/ISA720Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in Montanide ISA 720Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720
02

Targets

AMA1 (Apical membrane antigen 1)MSP1-19 (Plasmodium falciparum merozoite surface protein 1, C-terminal 19-kDa fragment)MSP1 (Merozoite surface protein 1)

Beyond the preview

Go deeper on Plasmodium falciparum Chimeric Protein 2.9 - Montanide ISA 720.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium falciparum Chimeric Protein 2.9 - Montanide ISA 720.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call